Anticoagulant Therapy for Venous Thromboembolism in Cancer

Anticoagulant Therapy for Venous Thromboembolism in Cancer

Direct oral anticoagulants were introduced for the treatment for acute venous thromboembolism just over a decade ago. Unlike warfarin, these drugs are given in fixed doses and do not require laboratory monitoring of the anticoagulant effect. Although direct oral anticoagulants are similar to warfari...

Full description

Saved in:
Bibliographic Details
Published in:The New England journal of medicine Vol. 382; no. 17; pp. 1650 - 1652
Main Author: Lee, Agnes Y.Y
Format: Journal Article
Language:English
Published: United States Massachusetts Medical Society 23-04-2020
Subjects:
Anticoagulants
Cancer
Clinical practice guidelines
Drug dosages
Health risk assessment
Hemorrhage
Humans
Medical prognosis
Neoplasms
Patients
Pyrazoles
Pyridones
Thromboembolism
Venous Thromboembolism
Warfarin
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Direct oral anticoagulants were introduced for the treatment for acute venous thromboembolism just over a decade ago. Unlike warfarin, these drugs are given in fixed doses and do not require laboratory monitoring of the anticoagulant effect. Although direct oral anticoagulants are similar to warfarin in efficacy, they are more convenient to use and are associated with a lower risk of major bleeding, particularly intracranial hemorrhage. These factors prompted a change in practice guidelines to recommend the use of direct oral anticoagulants as the first-line therapy over warfarin and transformed outpatient treatment for the majority of patients with acute venous thromboembolism. 1 . . .
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Editorial-2
ObjectType-Commentary-1
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMe2004220